We always aspire to be open and transparent to earn the trust and confidence of our stakeholders.
We work to achieve our business objectives responsibly for all
We support policies that promote the interests of patients, improve public health and promote access to medicines and innovations.
Public policy areas
We develop policy positions, adopt industry-leading standards, communicate openly and seek those who share our mission.
Access & affordability
Access & affordability
We work to save and improve lives around the world by inventing breakthrough medicines and vaccines – and ensuring they are available and affordable to patients who need them.
Innovation
Innovation
Innovation is the heart of our company. That's why we support policies that promote research & development investments and put patient needs first.
Public health
Public health
We take a firm stand on many public health issues confronting people and society today, including climate change, antimicrobial resistance and using water more efficiently, to name just a few.
Transparency & responsible behavior
Transparency & responsible behavior
We proactively address many legal and regulatory issues in our industry, such as clinical trial ethics, human rights and direct-to-consumer advertising.
Next: Humans, animals and the environment – our health is all connected
Addressing health equity in the age of COVID-19
In this Teal Talks episode, health care influencers Dr. Marcella Nunez-Smith and Dr. Aletha Maybank discuss how the pandemic has impacted health equity and disparities
Next: The impending “slow tsunami” of antimicrobial resistance
Addressing antibiotic resistance is more critical than ever. Here’s why.
Since their development, antibiotics have transformed health care and saved countless lives globally. But rising levels of antimicrobial resistance (AMR) make current antibiotics less effective. There’s no single or simple solution to the complex problem of AMR, but we’re committed to investing our expertise and resources alongside our partners to get much-needed antibiotics to those […]
Next: Humans, animals and the environment – our health is all connected
Addressing health equity in the age of COVID-19
In this Teal Talks episode, health care influencers Dr. Marcella Nunez-Smith and Dr. Aletha Maybank discuss how the pandemic has impacted health equity and disparities
Next: The impending “slow tsunami” of antimicrobial resistance
Addressing antibiotic resistance is more critical than ever. Here’s why.
Since their development, antibiotics have transformed health care and saved countless lives globally. But rising levels of antimicrobial resistance (AMR) make current antibiotics less effective. There’s no single or simple solution to the complex problem of AMR, but we’re committed to investing our expertise and resources alongside our partners to get much-needed antibiotics to those […]
Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2021 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
No Duty to Update
The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.
By continuing, you will be directed to a site intended only for residents of the United States and Canada. We are called MSD everywhere, except in the United States and Canada where we are known as Merck & Co Inc, Rahway, NJ USA.
